Cytotoxic activity of benzothiepins against human oral tumor cell lines. 2001

Y Sugita, and H Hosoya, and K Terasawa, and I Yokoe, and S Fujisawa, and H Sakagami
Faculty of Pharmaceutical Sciences, Josai University, Sakado, Saitama, Japan.

A total of 11 newly synthesized benzothiepins and structurally-related compounds were investigated for cytotoxic activity against both normal and tumor cells. All these compounds showed higher cytotoxic activity against three human oral tumor cell lines (HSC-2, HSC-3, HSG) than against normal human gingival fibroblast (HGF), suggesting tumor-specific cytotoxic action. In general, 3,4-dihydro-1-benzothiepin-5(2H)-ones [1-6] showed higher cytotoxic activity than 2,3-dihydro-1-benzothiepins [7-11]. Compounds 4 (4-bromo-3,4-dihydro-2-(2-oxo-2-phenylethyl)-1-benzothiepin-5(2H)-one), 5 (4-bromo-3,4-dihydro-2-(2-oxopropyl)-1-benzothiepin-5(2H)-one) and 6 (4-bromo-3,4-dihydro-2-[1-(methoxycarbonyl)-1-methylethyl]-1-benzothiepin-5(2H)-one), showed higher cytotoxic activity than compounds 1, 2 and 3, respectively, which had Cl instead of Br at C-4 position. Agarose gel electrophoresis demonstrated that these compounds induced large DNA fragments in oral tumor cells, whereas they produced smear pattern of smaller DNA fragments in human promyelocytic leukemia cells HL-60. These data suggest the medicinal efficacy of benzothiepins.

UI MeSH Term Description Entries
D009062 Mouth Neoplasms Tumors or cancer of the MOUTH. Cancer of Mouth,Mouth Cancer,Oral Cancer,Oral Neoplasms,Cancer of the Mouth,Neoplasms, Mouth,Neoplasms, Oral,Cancer, Mouth,Cancer, Oral,Cancers, Mouth,Cancers, Oral,Mouth Cancers,Mouth Neoplasm,Neoplasm, Mouth,Neoplasm, Oral,Oral Cancers,Oral Neoplasm
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D005881 Gingiva Oral tissue surrounding and attached to TEETH. Gums,Interdental Papilla,Papilla, Interdental,Gum
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001582 Benzothiepins
D012468 Salivary Gland Neoplasms Tumors or cancer of the SALIVARY GLANDS. Cancer of Salivary Gland,Non-Sebaceous Lymphadenomas,Salivary Gland Cancer,Salivary Gland Lymphadenomas,Sebaceous Lymphadenomas,Cancer of the Salivary Gland,Neoplasms, Salivary Gland,Cancer, Salivary Gland,Cancers, Salivary Gland,Gland Neoplasm, Salivary,Gland Neoplasms, Salivary,Lymphadenoma, Non-Sebaceous,Lymphadenoma, Salivary Gland,Lymphadenoma, Sebaceous,Lymphadenomas, Non-Sebaceous,Lymphadenomas, Salivary Gland,Lymphadenomas, Sebaceous,Neoplasm, Salivary Gland,Non Sebaceous Lymphadenomas,Non-Sebaceous Lymphadenoma,Salivary Gland Cancers,Salivary Gland Lymphadenoma,Salivary Gland Neoplasm,Sebaceous Lymphadenoma
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Y Sugita, and H Hosoya, and K Terasawa, and I Yokoe, and S Fujisawa, and H Sakagami
January 2003, Anticancer research,
Y Sugita, and H Hosoya, and K Terasawa, and I Yokoe, and S Fujisawa, and H Sakagami
January 2003, Anticancer research,
Y Sugita, and H Hosoya, and K Terasawa, and I Yokoe, and S Fujisawa, and H Sakagami
January 2005, Anticancer research,
Y Sugita, and H Hosoya, and K Terasawa, and I Yokoe, and S Fujisawa, and H Sakagami
January 2000, Anticancer research,
Y Sugita, and H Hosoya, and K Terasawa, and I Yokoe, and S Fujisawa, and H Sakagami
January 2001, Anticancer research,
Y Sugita, and H Hosoya, and K Terasawa, and I Yokoe, and S Fujisawa, and H Sakagami
January 2000, Anticancer research,
Y Sugita, and H Hosoya, and K Terasawa, and I Yokoe, and S Fujisawa, and H Sakagami
January 2005, In vivo (Athens, Greece),
Y Sugita, and H Hosoya, and K Terasawa, and I Yokoe, and S Fujisawa, and H Sakagami
March 2000, Phytomedicine : international journal of phytotherapy and phytopharmacology,
Y Sugita, and H Hosoya, and K Terasawa, and I Yokoe, and S Fujisawa, and H Sakagami
January 2001, Anticancer research,
Y Sugita, and H Hosoya, and K Terasawa, and I Yokoe, and S Fujisawa, and H Sakagami
January 2001, Anticancer research,
Copied contents to your clipboard!